ArticlePharmaceutics2018
Enhanced Delivery of 4-Thioureidoiminomethylpyridinium Perchlorate in Tuberculosis Models with IgG Functionalized Poly(Lactic Acid)-Based Particles.
Article in Pharmaceutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Actively Targeted Nanoparticles for Enhanced Diagnosis, Treatment, and Vaccination of Tuberculosis: A Systematic Review.International journal of nanomedicine · 2025Pooled it
- A novel method for screening antihyperuricemic drugs by combining aptamer sensor array, exonuclease III-DNA walker and linear discriminant analysis.Journal of pharmaceutical analysis · 2026Article
- Comparison of Autografts and Biodegradable 3D-Printed Composite Scaffolds with Osteoconductive Properties for Tissue Regeneration in Bone Tuberculosis.Biomedicines · 2023Article
- Article
- Polymer Particles Bearing Recombinant LEL CD81 as Trapping Systems for Hepatitis C Virus.Pharmaceutics · 2021Article
- Genetic Variation Putatively Associated withAntibiotics (Basel, Switzerland) · 2020Article
- Nano-based anti-tubercular drug delivery: an emerging paradigm for improved therapeutic intervention.Drug delivery and translational research · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
Abstract
The compound 4-thioureidoiminomethylpyridinium perchlorate (perchlozone
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.